The CRISPR genomic cure market has been gaining significant attention in recent years owing to the wide range of advantages that it offers. The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) associated protein-9 nuclease (Cas9) technology has enabled precise editing of genes inside cells and tissues, offering potential cures to various genetic diseases. Some of the key advantages that CRISPR offers are high efficiency and precision, simple design, multiple target sites, and reduced off-target effects. The increasing prevalence of genetic disorders and rising investments in R&D for genomic medicines are propelling the demand for CRISPR genomic cure. The Global CRISPR Genomic Cure Market is estimated to be valued at US$ 4.62 Bn in 2024 and is expected to exhibit a CAGR of 20.% over the forecast period 2024 To 2031.